Sabra Health (SBRA) Q3 2026 Earnings Call Transcript

Sabra Health Care REIT reported Q3 normalized FFO of $0.39 per diluted share and AFFO of $0.41, each up 8% year over year; same-store SHOP cash NOI rose 14.6%, with occupancy up 160bps to 89.2%. Management raised the 2026 guidance midpoints for normalized FFO and AFFO by $0.005 per share each, and reported $747.2 million in year-to-date investments plus $425 million in awarded deals. Net debt to adjusted EBITDA declined to 4.54x, and the company declared a $0.30 quarterly dividend, equal to 73% of Q3 normalized AFFO per share.

Analysis

The earnings signal is better than the headline growth rate alone, but its quality is mixed: occupancy and rate gains support organic SHOP growth, while acquisition volume and rent resets add a meaningful externally funded component. The key valuation question is whether acquired NOI clears the all-in cost of equity and debt after ongoing capital needs—not whether stated yields look attractive in isolation. ATM issuance can protect leverage while still diluting per-share growth, particularly if shares are sold below the forward agreement’s reference price; track shares outstanding and AFFO per share, not just portfolio NOI.

The strategic shift toward SHOP increases sensitivity to labor, occupancy execution, and operator performance versus a predominantly contractual rent stream. Current expense growth below revenue growth creates operating leverage, but that cuts both ways: a slowdown in move-ins or acuity mix could compress margins quickly. Near-term rent commencements and 2027 lease resets provide an earnings bridge, but lease-reset upside remains conditional on negotiations and operator ability to pay. Longer term, a larger SHOP footprint plus aging assets raises recurring CapEx risk; AFFO may overstate distributable cash if maintenance needs rise.

For the next 1–3 months, watch 2027 guidance, deal closings, and the equity issuance pace. Over 6–18 months, cap-rate expansion or higher funding costs could erase acquisition spreads even if property fundamentals remain sound. Consensus may be underweighting this capital-cost and dilution channel while extrapolating strong same-store results. The thesis weakens if SHOP same-store NOI growth materially decelerates, leverage reverses higher, or per-share guidance fails to convert pipeline growth into accretion.

Key Decisions for Investors

• Maintain a measured long bias in SBRA, preferably on market weakness rather than chasing the operating momentum; the near-term earnings bridge is supportive, but deal economics and equity dilution limit conviction. Reassess if AFFO-per-share guidance stalls despite portfolio growth.
• Track quarterly shares outstanding, ATM/forward settlements, and net debt/EBITDA alongside acquisition closings. Treat continued equity issuance without improving per-share growth—or leverage rising instead of trending down—as a thesis warning.
• Monitor SHOP same-store NOI, occupancy, and expense growth for margin inflection; a narrowing revenue-expense growth spread would challenge the operating-leverage case. Also track recurring CapEx disclosures as the acquired asset base matures.
• Do not capitalize the full skilled-nursing rent-reset opportunity yet. Upgrade the outlook only when negotiated resets are disclosed with effective dates, rent increases, and evidence that operator coverage remains sustainable; reimbursement or staffing-policy changes are key downside catalysts.